Exelixis | EXEL - Trade Debtors


Exelixis reported $328.95M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
Amgen USD 9.14B 432M Mar/2026
AstraZeneca USD 17.88B 1.17B Mar/2026
Bayer EUR 18.55B 4.36B Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Cytokinetics USD 6.83M 10.94M Mar/2026
Eisai JPY 227B 22.05B Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Exelixis USD 328.95M 42.03M Mar/2026
Genmab DKK 1.17B 119M Dec/2025
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
Incyte USD 1.05B 27.09M Mar/2026
Ionis Pharmaceuticals USD 74M 8M Mar/2026
MacroGenics USD 13.37M 55.86M Dec/2025
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Nektar Therapeutics USD 1.78M 1.12M Dec/2025
Neurocrine Biosciences USD 768.1M 81.3M Mar/2026
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Sanofi EUR 397M 186.13M Dec/2025
Takeda JPY 876.35B 118.43B Mar/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Xencor USD 12M 17.3M Mar/2026